Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jonesboro, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Carmichael, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Carmichael, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Escondido, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Escondido, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lancaster, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lancaster, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Los Gatos, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Los Gatos, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mission Viejo, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Newport Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Northridge, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Northridge, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Northridge, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Northridge, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oceanside, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Orangevale, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Orangevale, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Palm Springs, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Palm Spring, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Palm Spring, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Pasadena, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Pomona, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Pomona, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Santa Ana, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Santa Rosa, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Torrance, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Torrance, CA
Click here to add this to my saved trials